Orlistat: current status in clinical therapeutics

McClendon, Katie S.; Riche, Daniel M.; Uwaifo, Gabriel I.

doi:10.1517/14740330903321485

Cited by 65 publications

(50 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Orlistat, a gastrointestinal lipase inhibitor, has been evaluated in combination with a mildly reduced-calorie reduced-fat diet in overweight/obese patients with 49 or without T2DM 65 . Orlistat (120 mg 3x/day) has proven its efficacy and tolerability in 6-12-month placebo-controlled RCTs in overweight/obese patients with various background therapies (see references in Table 2).…”

Section: Orlistatmentioning

confidence: 99%

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Scheen

Gaal

2014

The Lancet Diabetes & Endocrinology

175

131

View full text Add to dashboard Cite

New glucose-lowering therapies, especially glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors, offer advantages over traditional antidiabetic agents by promoting weight loss while improving glucose control. . The present review will explore the overlapping pathophysiology and also how the various therapies can, alone or in combination, combat the 'dual burden' of obesity and T2DM. Word count: 249

show abstract

Section: Orlistatmentioning

confidence: 99%

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Scheen

Gaal

2014

The Lancet Diabetes & Endocrinology

175

131

View full text Add to dashboard Cite

show abstract

“…Orlistat is the only authorised anti-obesity drug approved from food and drug administration (FDA). It has been shown to act through inhibition of pancreatic lipase (PL), which is a key enzyme for the digestion of dietary triglycerides [26]. Orlistat is a saturated derivative of lipastatin, an inhibitor of PL isolated from the bacterium Streptomyces toxytricini [27].…”

Section: Introductionmentioning

confidence: 99%

Obesity: Development, Epidemiology, Factors Affecting, Quantity, Health Hazards, Management and Natural Treatment-a Review

Bollapragada

Shantaram

Kumar

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Due to the advancement in science, enhanced knowledge on the physiological aspects of almost all the tissues and the organs of the human body is gained. One of the most important prevalent topics needed for discussion is obesity and its effect on the metabolic changes leading to disorders in the human body such as diabetes, hypertension, cardiovascular diseases in addition to chronic diseases such as stroke, osteoarthritis, sleep apnea, some cancers, and inflammation-based pathologies. In recent years, obesity is a serious socioeconomic issue, which has become one of the major health problems all over the world, affecting people of all ages, sex, ethnicities and races. Obesity is a complex and multifactorial disease caused by the interaction of a myriad genetics, dietary, lifestyle and environmental factors and it is characterised by an excessive weight for height due to an enlarged fat deposition in the adipose tissue, which is due to a higher calorie intake than the energy expenditure. The pharmaceutical drugs are currently available to treat obesity but generally they have unpleasant side effects. Recent researches demonstrated the potential of natural products to counteract on obesity. Now the novel promising approach is the usage of dietary supplements and plant products and their bioactive compounds that could interfere on pancreatic lipase activity, food intake, lipid metabolism and adipocyte differentiation. In a similar way, hundreds of extracts are currently being isolated from plants, fungi, algae or bacteria and are screened for their potential inhibitions of activity against obesity. Natural products may have a synergistic activity that increases their bioavailability and action on multiple molecular targets.

show abstract

“…Mazindol is now available only in Japan [9]. In the 1990s, another type of antiobesity drug, orlistat, which inhibits lipid absorption in the intestine, was approved in the USA and Europe and is now also available [10]. Thereafter, sibutramine and rimonabant were developed; however, both drugs were withdrawn because of adverse effects [11].…”

Section: Introductionmentioning

confidence: 99%

Usefulness of Obese Animal Models in Antiobesity Drug Development

Ohta¹,

Murai²,

Yamada³

2017

Adiposity - Omics and Molecular Understanding

View full text Add to dashboard Cite

show abstract

Orlistat: current status in clinical therapeutics

Abstract: Orlistat's unique mechanism of action, beneficial effects on multiple co-morbidity surrogates and relatively mild adverse effect and drug interaction profile position it favorably as the first option for pharmacotherapy in comprehensive obesity management of adults and children.

Cited by 65 publications

References 148 publications

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

Obesity: Development, Epidemiology, Factors Affecting, Quantity, Health Hazards, Management and Natural Treatment-a Review

Usefulness of Obese Animal Models in Antiobesity Drug Development

Contact Info

Product

Resources

About